Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 49% Improvement Relative Risk Mortality (b) 55% c19early.org/d Efird et al. Vitamin D for COVID-19 EARLY TREATMENT Is early treatment with vitamin D beneficial for COVID-19? Retrospective 16,338 patients in the USA (March - September 2020) Lower mortality with vitamin D (not stat. sig., p=0.1) Efird et al., Int. J. Environmental Research and.., doi:10.3390/ijerph19010447 Favors vitamin D Favors control
The Interaction of Vitamin D and Corticosteroids: A Mortality Analysis of 26,508 Veterans Who Tested Positive for SARS-CoV-2
Efird et al., International Journal of Environmental Research and Public Health, doi:10.3390/ijerph19010447
Efird et al., The Interaction of Vitamin D and Corticosteroids: A Mortality Analysis of 26,508 Veterans Who Tested Positive.., International Journal of Environmental Research and Public Health, doi:10.3390/ijerph19010447
Dec 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 26,508 COVID+ veterans in USA, showing lower mortality with vitamin D use after testing positive (defined as being administered ≥7 days or half of the survival time within 2 weeks after testing), with statistical significance for hospitalized patients.
risk of death, 48.9% lower, RR 0.51, p = 0.10, treatment 11 of 544 (2.0%), control 413 of 15,794 (2.6%), adjusted per study, non-hospitalized patients, vitamin D + no corticosteroids vs. no vitamin D + no corticosteroids.
risk of death, 54.5% lower, RR 0.45, p = 0.02, treatment 11 of 192 (5.7%), control 553 of 4,340 (12.7%), NNT 14, adjusted per study, hospitalized patients, vitamin D + no corticosteroids vs. no vitamin D + no corticosteroids.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Efird et al., 31 Dec 2021, retrospective, USA, peer-reviewed, 10 authors, study period 1 March, 2020 - 10 September, 2020, dosage varies.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: International Journal of Environmental Research and Public Health Article The Interaction of Vitamin D and Corticosteroids: A Mortality Analysis of 26,508 Veterans Who Tested Positive for SARS-CoV-2 Jimmy T. Efird 1, *, Ethan J. Anderson 2 , Charulata Jindal 3 , Thomas S. Redding 1 , Andrew D. Thompson 1 , Ashlyn M. Press 1 , Julie Upchurch 1 , Christina D. Williams 1,4,5 , Yuk Ming Choi 6 and Ayako Suzuki 1,7,8 1 2 3 4 5 6 7 8 *   Citation: Efird, J.T.; Anderson, E.J.; Jindal, C.; Redding, T.S.; Thompson, A.D.; Press, A.M.; Upchurch, J.; Williams, C.D.; Choi, Y.M.; Suzuki, A. The Interaction of Vitamin D and Corticosteroids: A Mortality Analysis of 26,508 Veterans Who Tested Positive for SARS-CoV-2. Int. J. Environ. Res. Public Health 2022, 19, 447. https://doi.org/10.3390/ ijerph19010447 Academic Editor: Oliver Grundmann Received: 5 December 2021 Cooperative Studies Program Epidemiology Center, Durham VA Health Care System, Durham, NC 27705, USA; thomas.redding28@va.gov (T.S.R.); andrew.thompson3@va.gov (A.D.T.); ashlyn.press@va.gov (A.M.P.); julie.upchurch@va.gov (J.U.); christina.williams4@va.gov (C.D.W.); ayako.suzuki@duke.edu (A.S.) College of Pharmacy, University of Iowa, Iowa City, IA 52242, USA; ethan-anderson@uiowa.edu Harvard Medical School, Harvard University, Boston, MA 02115, USA; charujindal@gmail.com Department of Medicine, Duke University, Durham, NC 27710, USA Duke Cancer Institute, Duke University, Durham, NC 27710, USA Signify Health, Dallas, TX 75244, USA; ychoi@signifyhealth.com Division of Gastroenterology, Duke University, Durham, NC 27710, USA The Division of Gastroenterology, Durham VA Medical Center, Durham, NC 27705, USA Correspondence: jimmy.efird@va.gov; Tel.: +1-(650)-248-8282 Abstract: This data-based cohort consisted of 26,508 (7%) United States veterans out of the 399,290 who tested positive for SARS-CoV-2 from 1 March to 10 September 2020. We aimed to assess the interaction of post-index vitamin D (Vit D) and corticosteroid (CRT) use on 30-day mortality among hospitalized and non-hospitalized patients with coronavirus disease 2019 (COVID-19). Combination Vit D and CRT drug use was assessed according to four multinomial pairs (−|+, −|−, +|+, +|−). Respective categorical effects were computed on a log-binomial scale as adjusted relative risk (aRR). Approximately 6% of veterans who tested positive for SARS-CoV-2 died within 30 days of their index date. Among hospitalized patients, a significantly decreased aRR was observed for the use of Vit D in the absence of CRTs relative to patients who received CRTs but not Vit D (aRR = 0.30; multiplicity corrected, p = 0.0004). Among patients receiving systemically administered CRTs (e.g., dexamethasone), the use of Vit D was associated with fewer deaths in hospitalized patients (aRR = 0.51) compared with non-hospitalized patients (aRR = 2.5) (P-for-Interaction = 0.0071). Evaluating the effect of modification of these compounds in the context of hospitalization may aid in the management of COVID-19 and provide a better understanding of the pathophysiological mechanisms underlying this and future infectious disease outbreaks. Accepted: 28 December 2021 Published: 31 December 2021 Publisher’s Note: MDPI stays neutral Keywords: anti-inflammatory; corticosteroids; COVID-19; cytokine storm; SARS-CoV-2; vitamin D; veterans with regard to jurisdictional claims in published maps and institutional affiliations.
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit